Summary
Intuitive Surgical, Inc. (ISRG) in its 2013 10-K filing for the year ended December 30, 2012, reported robust revenue growth of 24% to $2.18 billion, driven by a 25% increase in da Vinci procedures performed globally, reaching approximately 450,000. This growth was fueled by strong performance in U.S. gynecologic and general surgery procedures, as well as international prostatectomies, partially offset by a decline in U.S. prostatectomies due to changes in PSA screening recommendations and disease management. The company continues to see a favorable trend in recurring revenue from instruments, accessories, and service, which now represents 57% of total revenue. This recurring revenue stream is a key indicator of customer stickiness and ongoing system utilization. ISRG also demonstrated strong operational execution with a 26% increase in operating income and a healthy cash flow from operations, ending the year with nearly $3 billion in cash, cash equivalents, and investments. The company continues to invest in research and development to expand its product portfolio, including new instruments and imaging technologies.
Financial Highlights
48 data points| Revenue | $2.18B |
| Cost of Revenue | $608.50M |
| Gross Profit | $1.57B |
| R&D Expenses | $170.00M |
| SG&A Expenses | $522.20M |
| Operating Expenses | $692.20M |
| Operating Income | $878.10M |
| Net Income | $656.60M |
| EPS (Basic) | $1.83 |
| EPS (Diluted) | $1.78 |
| Shares Outstanding (Basic) | 358.20M |
| Shares Outstanding (Diluted) | 369.90M |
Key Highlights
- 1Total revenue increased by 24% to $2.18 billion in 2012.
- 2Global da Vinci procedures increased by 25% to approximately 450,000 in 2012.
- 3Recurring revenue (instruments, accessories, and service) grew 27% and represented 57% of total revenue.
- 4Operating income grew 26% to $878.1 million.
- 5The company sold 620 da Vinci Surgical Systems in 2012, an increase from 534 in 2011.
- 6Ended the year with $2.92 billion in cash, cash equivalents, and investments.
- 7U.S. Prostatectomy (dVP) procedures saw a 15% decline, attributed to changes in PSA screening and non-surgical disease management.